Effects of Long-term Rofecoxib on Gastric Intestinal Metaplasia: Results of a Randomized Controlled Trial

Wai K. Leung, Enders K. Ng, Francis K.l. Chan, Wing Y. Chan, Kui-fat Chan, Alex Au-Yeung, Candice C. Lam, James Y. Lau, Joseph J.�y. SungClinical 2006 · DOI

Abstract

There was no trend to suggest that treatment with rofecoxib for 2 years resulted in the regression of gastric IM. Although our findings cast doubt on the reversibility of gastric IM by COX-2 inhibitor, further studies are needed to establish the role of COX-2 inhibitors in different stages of gastric carcinogenesis.
BibTeX
@inproceedings{leung2006effects,
  author = {Wai K. Leung and Enders K. Ng and Francis K.L. Chan and Wing Y. Chan and Kui-fat Chan and Alex Au-Yeung and Candice C. Lam and James Y. Lau and Joseph J.�Y. Sung},
  title = {{Effects of Long-term Rofecoxib on Gastric Intestinal Metaplasia: Results of a Randomized Controlled Trial}},
  booktitle = {Clinical},
  year = {2006},
  doi = {10.1158/1078-0432.ccr-06-0693},
}

Loading related content...

Figure